Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

The prospect of discovering new biomarkers for ovarian cancer based on current knowledge of susceptibility loci and genetic variation (Review)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The collagen receptor uparap in malignant mesothelioma: A potential diagnostic marker and therapeutic target

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Classification of MSH6 Variants of Uncertain Significance Using Functional Assays

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Gastrin and the moderate hypergastrinemias

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Osteosarcoma and Metastasis Associated Bone Degradation-A Tale of Osteoclast and Malignant Cell Cooperativity

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. DNA Methylation in Ovarian Tumors-a Comparison Between Fresh Tissue and FFPE Samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Ovarian cancer is the most lethal gynaecological malignancy. The cancer initially presents with non‑specific symptoms; thus, it is typically not discovered until the patient has reached the late, considerably more lethal, stages of the disease. Research focus is currently on finding novel biomarkers, especially for early detection and stratification of the disease. One promising approach has been to focus on mutations or variations in the genetic code that are associated with the risk of developing ovarian cancer. A certain heritable component is already known regarding genes such as BRCA1/2, TP53, MSH6, BRIP1 and RAD51C, yet these are estimated to only account for ~3.1% of the total risk. Recent advances in sequencing technologies have enabled the investigation of hundreds of thousands of genetic variants in genome‑wide association studies in tens of thousands of patients, which has led to the discovery of 108 (39 loci with P<5.0x10‑8) novel susceptibility loci for ovarian cancer, presented in this review. Using the published variants in a patient cohort screening, together with variants identified in our ongoing whole exome sequencing project, future aims are to ascertain whether certain of the novel variants could be used as biomarkers for early diagnosis and/or treatment decisions.

OriginalsprogEngelsk
TidsskriftInternational Journal of Molecular Sciences
Vol/bind44
Udgave nummer5
Sider (fra-til)1599-1608
Antal sider10
ISSN1661-6596
DOI
StatusUdgivet - nov. 2019

ID: 59089279